Appendix 2

Reviewer Relationships With Industry and Other Entities—2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)

ReviewerRepresentationConsultantSpeaker's BureauOwnership/Partnership/PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
Hugh CalkinsOfficial Reviewer–HRS and ACCF/AHA Task Force on Performance Measures
  • Medtronic

NoneNone
  • Medtronic

NoneNone
A. John CammOfficial Reviewer–ACCF Board of Trustees
  • ARYx Pharmaceuticals

  • Boehringer Ingelheim

  • Daiichi Sankyo

  • Medtronic

  • Portola Pharmaceuticals

NoneNoneNoneNone
  • 2009, Plaintiff arbitration procedure

Christopher B. GrangerOfficial Reviewer–AHA
  • AstraZeneca

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

NoneNone
  • AstraZeneca

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

NoneNone
Jonathan L. HalperinOfficial Reviewer–AHA and ACCF/AHA Task Force on Practice Guidelines Lead Reviewer
  • Boehringer Ingelheim

  • Daiichi Sankyo

  • Portola Pharmaceuticals

NoneNoneNoneNoneNone
Bradley P. KnightOfficial Reviewer–HRSNone
  • Medtronic

None
  • Medtronic

NoneNone
Allen J. SolomonOfficial Reviewer–ACCF Board of GovernorsNoneNoneNoneNoneNoneNone
Ralph G. BrindisContent ReviewerNoneNoneNoneNoneNoneNone
Mark S. LinkContent ReviewerNoneNoneNoneNoneNoneNone
Frederick A. MasoudiContent Reviewer–ACCF/AHA Task Force on Performance MeasuresNoneNoneNoneNoneNoneNone
Robert L. McNamaraContent Reviewer–ACCF/AHA Atrial Fibrillation Data Standards Committee
  • Boehringer Ingelheim

NoneNoneNoneNone
  • 2010, Defendant anticoagulation

Paul J. WangContent Reviewer–ACCF Electrophysiology Committee
  • Medtronic

NoneNoneNoneNoneNone

This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.

ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; and HRS, Heart Rhythm Society.

  • Significant (greater than $10 000) relationship.